Share on facebook
Share on twitter
Share on linkedin

This Medical Moment – Season 2, Episode 3 – Medical Influence Goes Digital

The pharmaceutical industry has long relied on partnering with key opinion leaders (KOLs) for their insights, credibility, and influence – from the drug development process to raising awareness and adoption of new treatments. But the combination of a post pandemic world and an ever-changing market has changed the dynamics of where and how opinions are expressed. 

Insert the rising wave of digital opinion leaders (DOLs). These emerging stars pack a triple punch – they’re digital natives, they captivate audiences online with their expertise, and they utilize personalized & interactive approaches to share valuable insights.  

In the latest episode of This Medical Moment, PRECISIONscientia’s Director of KOL Data Solutions, Read Roberts, discusses the growing landscape of DOLs, including: 

  • Pharma’s KOL identification challenges and the DOL solution 
  • The definition of a digital opinion leader and their influence 
  • The difference between traditional KOLs and cutting-edge DOLs 
  • How to measure the success of DOL campaigns  
  • A special glimpse into DOL MAP, the award-winning platform that identifies, evaluates, and engages with these rising stars 

Never Miss a Medical Moment

The most extraordinary moments in medicine are happening right now, but will these innovations get the opportunity to change lives?

Stay in the know and be the first to watch new episodes of This Medical Moment.


Advancements are happening in every corner of medicine. Brilliant new innovations are upending traditional thinking and power structures in the development of treatments and the delivery of care.

Join Carolyn Morgan in This Medical Moment and learn how others are overcoming the obstacles. She will be joined by guests who are leading critical changes in the standards of care.

What’s coming next? Find out. In a moment.

Accelerating clinical research and development through the combined power of trials, labs, and data science.

Demonstrating the value of life-science innovations with evidence and real-world expertise.